Jupiter Investment Management’s Pacira BioSciences PCRX Stock Holding History

Jupiter Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$7.37M	Buy	+140,393	New	+$5.87M	0.12%	163

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Jupiter Investment Management's PCRX Position: Q2 2020 in Review

Jupiter Investment Management opened a new position in Pacira BioSciences (PCRX) in Q2 2020: 140,393 shares worth $7.37M. The stake represents 0.12% of the portfolio and ranks #163 among its holdings.

248 funds tracked by Wall St. Rank hold PCRX as of Q2 2020.

Jupiter Investment Management held 140,393 shares of Pacira BioSciences worth $7.37M as of Q2 2020.
Pacira BioSciences was a new Jupiter Investment Management position in Q2 2020.
Pacira BioSciences made up 0.12% of Jupiter Investment Management's portfolio in Q2 2020, its #163 holding.
248 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2020.

Based on Jupiter Investment Management's 13F filing for Q2 2020, filed 13 Jul 2020.